Formulation technologies and advances for oral delivery of novel nitroimidazoles and antimicrobial peptides.
作者： John Ndayishimiye , Amirali Popat , Mark Blaskovich , James Robert Falconer
DOI: 10.1016/J.JCONREL.2020.05.002
关键词:
摘要: … Antibiotic resistance has become a global crisis, driving the exploration for novel antibiotics and novel … efforts two classes of antibiotics, bicyclic nitroimidazoles and antimicrobial …
uq.edu.au参考文章(289)
R. Craig MacLean, Alvaro San Millan, The evolution of antibiotic resistance Science. ,vol. 365, pp. 1082- 1083 ,(2019) , 10.1126/SCIENCE.AAX3879
David T. Thwaites, Barry H. Hirst, Nicholas L. Simmons, Passive transepithelial absorption of thyrotropin-releasing hormone (TRH) via a paracellular route in cultured intestinal and renal epithelial cell lines. Pharmaceutical Research. ,vol. 10, pp. 674- 681 ,(1993) , 10.1023/A:1018947430018
Brian Davies, Tim Morris, Physiological Parameters in Laboratory Animals and Humans Pharmaceutical Research. ,vol. 10, pp. 1093- 1095 ,(1993) , 10.1023/A:1018943613122
Fry J, Lacey Bw, Garrod Lp, Wheatley D, Nabarro Jd, Batten Lw, Joules H, Cohen H, Discussion on the use and abuse of antibiotics. Journal of the Royal Society of Medicine. ,vol. 48, pp. 355- 364 ,(1955)
Akira Tsuji, Ikumi Tamai, Carrier-Mediated Intestinal Transport of Drugs Pharmaceutical Research. ,vol. 13, pp. 963- 977 ,(1996) , 10.1023/A:1016086003070
Josias H Hamman, Gill M Enslin, Awie F Kotz??, Oral delivery of peptide drugs: barriers and developments. BioDrugs. ,vol. 19, pp. 165- 177 ,(2005) , 10.2165/00063030-200519030-00003
C. Webster Andrews, Lee Bennett, Lawrence X. Yu, Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharmaceutical Research. ,vol. 17, pp. 639- 644 ,(2000) , 10.1023/A:1007556711109
Howard L. Holley, Allen E. Hussar, Antibiotics and antibiotic therapy : a clinical manual Macmillan. ,(1954)
, Combating antimicrobial resistance: policy recommendations to save lives. Clinical Infectious Diseases. ,vol. 52, ,(2011) , 10.1093/CID/CIR153
R.H Müller, C Jacobs, O Kayser, Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future Advanced Drug Delivery Reviews. ,vol. 47, pp. 3- 19 ,(2001) , 10.1016/S0169-409X(00)00118-6